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Exposure of laboratory mice to carbon nanotubes mimics exposure to asbestos, from 
initial and chronic inflammation, through loss of the same tumour-suppressor 
pathways and eventual sporadic development of malignant mesothelioma.  Fibres of a 
similar nature may pose significant health risks to humans. 
 
 
Malignant pleural mesothelioma (MPM) is an incurable cancer of the epithelial lining of the 
lungs and chest cavity [1]. Diagnosis is notoriously difficult, treatment options (inclusive of 
surgery) are severely limited and most patients succumb to the disease within one to two 
years of diagnosis [2]. Historically, this disease is causally linked to direct high-volume 
exposure to fibrous asbestos, particularly amongst asbestos miners, construction workers and 
ship-builders. Commercial use of asbestos is consequently banned in Western society 
although its use continues unabated in several emerging economies. There is increasing 
awareness of the threat posed by environmental and secondary exposures, and a legacy of 
asbestos-insulated buildings continues to drive new cases of MPM in countries where its 
active use has long ceased [3]. Moreover, there is growing concern amongst scientists that 
materials with physical properties similar to asbestos, such as carbon nanotubes, might pose 
an equivalent human health threat [4]. Given the extremely long latency between exposure 
and asbestos-driven MPM (typically up to 40 years), it may be decades before the actual 
threat posed by such materials manifests as malignancy. 
 Precisely how asbestos causes mesothelioma has been debated for decades. The 
epidemiology of MPM indicates that long fibrous types of asbestos (for example, amosite or 
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crocidolite) pose a much greater threat than more particulate specimen (for example, 
serpentine or chryostile) [5]. The long-term persistence of fibres in the pleura is thought to 
drive chronic inflammation, and the continued exposure of pleural epithelium to mitogens 
and growth-promoting cytokines likely supports ectopic cell proliferation [6]. Iron deposits in 
some forms of asbestos are linked to generation of reactive oxygen species that can similarly 
promote proliferation by altering protein function and, at high concentrations, drive 
mutagenesis [7]. Additionally, asbestos fibres have been proposed to physically interfere with 
chromosome condensation and the fidelity of chromosome segregation during mitosis [8]. A 
landmark study in rodents demonstrated that fibrous asbestos cannot be efficiently cleared 
by macrophages (engendering the term ‘frustrated phagocytosis’) leading to chronic 
inflammation, whereas the same material milled into a fine powder is efficiently cleared and 
the accompanying acute inflammation quickly resolved [9]. The study strongly suggests that 
the physical attributes of fibrous asbestos (rather than its chemical composition) are the 
primary determinant of MPM risk. Ominously, high aspect-ratio carbon nanotubes that 
physically resemble fibrous asbestos similarly resist phagocytosis, drive chronic inflammation 
and were previously shown to predispose rodents to peritoneal mesothelioma when injected 
into the abdominal cavity, suggesting that such materials may pose a significant hazard akin 
to asbestos [10–12]. 
A new study by Chernova et al. [13] in this issue of Current Biology is the first to 
directly compare the progressive pathological response of mice to intra-pleural injection of 
long-fibre asbestos (LFA) with that of long-fibre carbon nanotubes (CNT). Examination of 
exposed tissue at one and twelve weeks post inoculation revealed a similar degree of chronic 
inflammation induced by either fibre type. Transcriptomic profiling of exposed tissue showed 
a pattern of altered gene expression that was remarkably similar for tissue exposed to long-
fibre forms of either LFA and CNT, as compared with vehicle control or indeed tissue expose 
to short-fibre forms of either. Phospho-protein profiling moreover revealed that exposure to 
either CNT or LFA drives activation of the same signal transduction pathways that are 
commonly perturbed in human MPM, notably including the SRC, FAK, ERK, AKT/mTORC1 and 
STAT pathways [14], and that the degree of activation was strikingly similar for both fibre 
types. By 6 months, the inflammatory lesions showed a sustained increase in proliferation and 
oxidative DNA damage in both the asbestos and CNT cohorts and, by 12-20 months, 10-25% 
of animals exposed to CNT (3 independent cohorts) and 9% of animals exposed to asbestos 
developed pleural mesothelioma. Disease latency was moreover identical for both fibre types. 
Both LFA- and CNT-induced tumours exhibited histopathology and immuno-histochemical 
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markers consistent with human MPM, including mesothelial lineage markers, cytokeratins, 
and WT1. The study thus conclusively demonstrates that carbon nanotubes with asbestos-like 
dimensions drive the same disease as long-fibre asbestos and thus present a comparable risk. 
 
A significant advantage of such longitudinal analysis in an animal model is the capacity 
to investigate early-stage disease and indeed progression from pre-malignant lesions to 
malignancy. By comparison, studies of human MPM have to date been largely restricted to 
late-stage disease, owing to prolonged disease latency, late presentation and the current lack 
of predictive clinical indicators of progression from benign asbestos-related pleural effusion 
to malignancy (note that approximately 15% of patients presenting with pleural effusion 
eventually progress to MPM). The recent comprehensive genomic characterization of human 
MPM has shown that the majority of end-stage disease cases contain loss-of-function 
mutations in one or more of three key tumour-suppressor loci, namely CDKN2A, NF2 and 
BAP1 [15], however, the status of these genes in pre-malignant disease is presently unknown.   
Loss of CDKN2A occurs in approximately 50% of human MPM [16]. In the present 
study, Chernova and colleagues examined expression of the protein products of Cdkn2a 
during progression to malignancy [13]. This gene encodes two important tumour-suppressor 
proteins that function in distinct pathways: p16INK4a blocks progress through the cell cycle by 
inhibiting CDK4/Cyclin D, whereas p14ARF (p19Arf in mouse) antagonizes MDM2-dependent 
p53 degradation. In vivo mouse models have shown that both p16Ink4a and p19Arf proteins 
suppress asbestos-induced tumourigenesis and, although p19Arf must be lost for 
mesothelioma pathogenesis to occur, inactivation of both Cdkn2a gene products cooperate to 
accelerate asbestos-induced tumourigenesis [17]. Consistent with this, Chernova et al. [13] 
detected reduced mRNA and protein expression of both p19Arf and p16Ink4a in tumours 
induced by either LFA or CNT, along with allelic loss of p19Arf in tumours induced by CNT.  
Somewhat surprisingly, allelic loss of p19Arf-encoding sequences occurred in the absence of 
deletion of p16Ink4a-encoding sequence, suggesting that the two pathways are subject to 
distinct selective pressures. Importantly, examination of pre-malignant inflammatory lesions 
also revealed sporadic loss of p19Arf and p16Ink4a protein and mRNA expression, this time in 
the absence of allelic loss, suggesting an epigenetic mechanism of Cdkn2a suppression in pre-
malignant lesions. The CDKN2A locus is silenced through CpG-island hypermethylation in 
multiple human cancers and, accordingly, bisulphite sequencing of the locus in pre-malignant 
chronic inflammatory lesions showed hypermethylation of CpG islands within and adjacent to 
both p19Arf and p16Ink4a-coding sequences in mice exposed to either LFA or CNT. These data 
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would suggest that epigenetic silencing of the Cdkn2a locus occurs prior to progression to 
malignancy and that progression is associated with further selective pressure to delete the 
locus, in particular the p19Arf-encoding regions.  
As noted above, Cdkn2A is one of three loci that show a high frequency of loss-of-
function mutation in human MPM, the others being BAP1 and NF2. Surprisingly, tumours 
induced by either LFA or CNT showed no loss of NF2 protein expression whereas 
immunohistochemistry for BAP1 suggested preferential cytosolic localisation occurring in 
both instances. Although again demonstrating clear molecular similarities between 
progressive disease induced by LFA and that induced by CNT, these data also point to the 
need for further in vivo investigation of the molecular, cellular, and intercellular processes 
that drive disease evolution from the pre-malignant state to clinical MPM. 
Several outstanding questions remain: Do reactive oxygen species play a direct role in 
driving the epigenetic changes detected in pre-malignant lesions? Why is hypermethylation-
induced silencing of Cdkn2a not sufficient for progression to malignancy and what is the 
selective pressure for locus deletion to occur subsequent to gene silencing? A possible answer 
may lie in the fact that CDKN2B, syntenic with CDKN2A on chromosome 9p21.3, is co-deleted 
in the vast majority of MPM cases with loss of CDKN2A [18]. What is unquestionably clear 
from this study is that carbon nanotubes (and potentially other high-aspect-ratio fibres) 
present the same carcinogenic hazard as does long-fibre asbestos. Carbon nanotubes have a 
broad spectrum of commercial uses, ranging from use in automotive parts, sports equipment 
and boat hulls to more direct contact via use in water filtration and drug formulation [19], 
presenting substantial opportunity for exposure during manufacturing or later, due to 
attrition of materials containing CNT. The study by Chernova and colleagues [13] presents a 
clear opportunity to mitigate against future MPM epidemics through legislation and tighter 
regulation of CNT production, use and disposal. 
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Figure 1. Identical disease progression after injection of long-fibre asbestos or carbon nanotubes 
Intra-pleural injection of either long-fibre asbestos (LFA) or carbon nanotubes (CNT) drives 
equivalent acute inflammation, followed by frustrated phagocytosis, leading to chronic 
inflammation. Sustained growth-factor signalling and continued exposure to reactive oxygen 
species eventually leads to transformation of pleural epithelial cells. Epigenetic silencing of Cdkn2a 
is subsequently found in pre-malignant inflammatory lesions, with sporadic deletion of p19Arf 
and/or p16Ink4a-encoding sequences appearing later, coincident with progression to malignant 
pleural mesothelioma. Progressive disease appears to be agnostic to fibre composition and rather 
is dependent upon fibre dimensions and bio-persistence. 
